CA3105731A1 - Polymeric nanoparticles comprising salinomycin - Google Patents

Polymeric nanoparticles comprising salinomycin Download PDF

Info

Publication number
CA3105731A1
CA3105731A1 CA3105731A CA3105731A CA3105731A1 CA 3105731 A1 CA3105731 A1 CA 3105731A1 CA 3105731 A CA3105731 A CA 3105731A CA 3105731 A CA3105731 A CA 3105731A CA 3105731 A1 CA3105731 A1 CA 3105731A1
Authority
CA
Canada
Prior art keywords
peg
cancer
poly
pharmaceutical composition
pla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3105731A
Other languages
English (en)
French (fr)
Inventor
Surender Kharbanda
James Hill
Sireesh APPAJOSYULA
Mark Rosenberg
Harpal Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tharimmune Inc
Original Assignee
Hillstream Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hillstream Biopharma Inc filed Critical Hillstream Biopharma Inc
Publication of CA3105731A1 publication Critical patent/CA3105731A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3105731A 2018-07-18 2019-07-18 Polymeric nanoparticles comprising salinomycin Pending CA3105731A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862699963P 2018-07-18 2018-07-18
US62/699,963 2018-07-18
PCT/US2019/042382 WO2020018778A1 (en) 2018-07-18 2019-07-18 Polymeric nanoparticles comprising salinomycin

Publications (1)

Publication Number Publication Date
CA3105731A1 true CA3105731A1 (en) 2020-01-23

Family

ID=67704555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3105731A Pending CA3105731A1 (en) 2018-07-18 2019-07-18 Polymeric nanoparticles comprising salinomycin

Country Status (8)

Country Link
US (1) US20200046648A1 (https=)
EP (1) EP3823589A1 (https=)
JP (1) JP2021530504A (https=)
KR (1) KR20210053881A (https=)
CN (1) CN113164375A (https=)
AU (1) AU2019307629A1 (https=)
CA (1) CA3105731A1 (https=)
WO (1) WO2020018778A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186633A1 (en) * 2020-06-30 2022-01-06 Hillstream Biopharma Inc. Nanoparticles and methods of manufacture thereof
WO2022251844A1 (en) * 2021-05-25 2022-12-01 Hillstream Biopharma, Inc. Polymeric nanoparticles comprising chemotherapeutic compounds and related methods
CN116570584B (zh) * 2023-05-08 2025-02-18 广州白云山医药集团股份有限公司白云山制药总厂 盐霉素在制备降尿酸和/或治疗高尿酸血症的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165987A1 (en) 2002-04-05 2006-07-27 Patrice Hildgen Stealthy polymeric biodegradable nanospheres and uses thereof
AU2006278718B2 (en) 2005-08-03 2010-10-07 Secura Bio Inc. Use of HDAC inhibitors for the treatment of myeloma
KR101445405B1 (ko) 2006-07-28 2014-09-26 가부시키가이샤 브리지스톤 상간 영역을 갖는 중합체성 코어-쉘 나노입자
US20080081075A1 (en) 2006-10-02 2008-04-03 National Tsing Hua University Multifunctional mixed micelle of graft and block copolymers and preparation thereof
US9149426B2 (en) 2012-02-15 2015-10-06 University Of Tennessee Research Foundation Nanoparticle composition and methods to make and use the same
EP3778696A1 (en) 2012-04-23 2021-02-17 NanoProteagen Ltd. Polymeric nanoparticles and a process of preparation thereof
WO2018049155A1 (en) * 2016-09-08 2018-03-15 Dana-Farber Cancer Institute, Inc. Compositions comprising polymeric nanoparticles and mcl-1 antagonists
MY210233A (en) * 2017-10-11 2025-09-04 Illustris Pharmaceuticals Inc Methods and compositions for topical delivery
WO2019104001A1 (en) * 2017-11-22 2019-05-31 Hillstream Biopharma Inc. Polymeric nanoparticles comprising bortezomib

Also Published As

Publication number Publication date
KR20210053881A (ko) 2021-05-12
AU2019307629A1 (en) 2021-02-18
US20200046648A1 (en) 2020-02-13
WO2020018778A1 (en) 2020-01-23
JP2021530504A (ja) 2021-11-11
CN113164375A (zh) 2021-07-23
EP3823589A1 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
JP6396288B2 (ja) ポリマーナノ粒子およびその調整のプロセス
CA2623293A1 (en) Nanoparticles for targeted delivery of active agents
US20220175688A1 (en) Polymeric nanoparticles
US20200046648A1 (en) Polymeric nanoparticles comprising salinomycin
AU2016326747A1 (en) Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
WO2018049155A1 (en) Compositions comprising polymeric nanoparticles and mcl-1 antagonists
JP2019537600A (ja) ポリマーナノ粒子
US10695427B2 (en) Shape memory particles for biomedical uses
Cui et al. Comparison of virus-capsid mimicking biologic-shell based versus polymeric-shell nanoparticles for enhanced oral insulin delivery
US20190151340A1 (en) Polymeric nanoparticles comprising bortezomib
KR20120115441A (ko) 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법
US20210128675A1 (en) Lhrh-paclitaxel conjugates and methods of use
US20210128674A1 (en) Lhrh-conjugated prodigiosin and uses thereof
WO2022251844A1 (en) Polymeric nanoparticles comprising chemotherapeutic compounds and related methods
HK40043814A (en) Polymeric nanoparticles and a process of preparation thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240829